ATE516803T1 - Aryl-spirohydantoin-cgrp-rezeptor-antagonisten - Google Patents
Aryl-spirohydantoin-cgrp-rezeptor-antagonistenInfo
- Publication number
- ATE516803T1 ATE516803T1 AT04719322T AT04719322T ATE516803T1 AT E516803 T1 ATE516803 T1 AT E516803T1 AT 04719322 T AT04719322 T AT 04719322T AT 04719322 T AT04719322 T AT 04719322T AT E516803 T1 ATE516803 T1 AT E516803T1
- Authority
- AT
- Austria
- Prior art keywords
- aryl
- receptor antagonists
- cgrp receptor
- spirohydantoin
- compounds
- Prior art date
Links
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 2
- QAHZIGHCEBUNGT-QMGFNSACSA-N (5r,6s,7s,8r,9r)-6,7,8-trihydroxy-9-(hydroxymethyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)C[C@]11C(=O)NC(=O)N1 QAHZIGHCEBUNGT-QMGFNSACSA-N 0.000 title 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 2
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45491703P | 2003-03-14 | 2003-03-14 | |
| PCT/US2004/007686 WO2004082678A1 (en) | 2003-03-14 | 2004-03-10 | Aryl spirohydantoin cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516803T1 true ATE516803T1 (de) | 2011-08-15 |
Family
ID=33029928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04719322T ATE516803T1 (de) | 2003-03-14 | 2004-03-10 | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7189722B2 (de) |
| EP (1) | EP1605936B1 (de) |
| JP (1) | JP4673296B2 (de) |
| AT (1) | ATE516803T1 (de) |
| AU (1) | AU2004222328B2 (de) |
| CA (1) | CA2518843A1 (de) |
| WO (1) | WO2004082678A1 (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| US7205293B2 (en) * | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| US7569578B2 (en) | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| US7659300B2 (en) * | 2004-09-08 | 2010-02-09 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirolactam CGRP receptor antagonists |
| ATE537153T1 (de) * | 2004-09-09 | 2011-12-15 | Merck Sharp & Dohme | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors |
| ATE464305T1 (de) | 2004-09-13 | 2010-04-15 | Merck Sharp & Dohme | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors |
| ATE518852T1 (de) * | 2004-09-13 | 2011-08-15 | Merck Sharp & Dohme | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten |
| US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| ES2433251T5 (es) | 2005-11-14 | 2020-03-13 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos |
| EP1951042B1 (de) * | 2005-11-18 | 2012-10-10 | Merck Sharp & Dohme Corp. | Spirolactam tricyclische cgrp-rezeptor-antagonisten |
| US8071770B2 (en) | 2005-11-18 | 2011-12-06 | Merck Sharp & Dohme Corp. | Spirohydantoin aryl CGRP receptor antagonists |
| WO2007061677A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam aryl cgrp receptor antagonists |
| WO2007061694A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin tricyclic cgrp receptor antagonists |
| BRPI0711352A2 (pt) | 2006-05-09 | 2011-09-27 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular |
| CA2658573A1 (en) * | 2006-07-21 | 2008-01-24 | Vertex Pharmaceuticals Incorporated | Cgrp receptor antagonists |
| EP2091533B1 (de) * | 2006-12-08 | 2012-11-28 | Merck Sharp & Dohme Corp. | Eingeschränkte spirocyclische verbindungen als cgrp-rezeptor-antagonisten |
| AU2008239754A1 (en) * | 2007-04-11 | 2008-10-23 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups |
| WO2008130524A1 (en) * | 2007-04-16 | 2008-10-30 | Merck & Co., Inc. | Aryl heterocyclic cgrp receptor antagonists |
| JP2010524931A (ja) * | 2007-04-16 | 2010-07-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 二環式アニリドヘテロ環式ｃｇｒｐ受容体アンタゴニスト |
| EP2161996B1 (de) * | 2007-06-05 | 2014-07-16 | Merck Sharp & Dohme Corp. | Heterocyclische carboxamid-cgrp-rezeptorantagonisten |
| JP2010529120A (ja) * | 2007-06-07 | 2010-08-26 | メルク・シャープ・エンド・ドーム・コーポレイション | 三環式アニリド複素環ｃｇｒｐ受容体アンタゴニスト |
| WO2009109911A1 (en) | 2008-03-04 | 2009-09-11 | Pfizer Limited | Methods of treating chronic pain |
| WO2010027927A1 (en) * | 2008-09-08 | 2010-03-11 | Merck Sharp & Dohme Corp. | Monocyclic amide cgrp receptor antagonists |
| US7815880B2 (en) * | 2008-09-30 | 2010-10-19 | Calera Corporation | Reduced-carbon footprint concrete compositions |
| ES2912569T3 (es) | 2009-08-28 | 2022-05-26 | Teva Pharmaceuticals Int Gmbh | Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina |
| NZ732875A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| SG10201604040PA (en) | 2011-05-20 | 2016-07-28 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
| RS66303B1 (sr) | 2011-05-20 | 2025-01-31 | H Lundbeck As | Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene |
| WO2013169574A2 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| AU2017331593B2 (en) | 2016-09-23 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| EP3366286A1 (de) | 2017-02-22 | 2018-08-29 | Johannes Keller | Verbindungen zur behandlung von sepsis |
| AR111665A1 (es) * | 2017-05-15 | 2019-08-07 | Lilly Co Eli | Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp |
| JP6794582B2 (ja) * | 2017-05-15 | 2020-12-02 | イーライ リリー アンド カンパニー | Ｃｇｒｐ受容体拮抗薬 |
| PE20211707A1 (es) | 2019-01-08 | 2021-09-01 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3561198D1 (en) | 1984-03-23 | 1988-01-28 | Pfizer | Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications |
| JP3449084B2 (ja) * | 1995-12-25 | 2003-09-22 | 富士レビオ株式会社 | ヒダントイン誘導体 |
| WO2004082605A2 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co. Inc. | Bicyclic anilide spirohydantoin cgrp receptor antagonists |
| US7192954B2 (en) * | 2003-03-14 | 2007-03-20 | Merck & Co., Inc. | Monocyclic anilide spirohydantoin CGRP receptor antagonists |
-
2004
- 2004-03-10 AT AT04719322T patent/ATE516803T1/de not_active IP Right Cessation
- 2004-03-10 US US10/547,227 patent/US7189722B2/en not_active Expired - Lifetime
- 2004-03-10 EP EP04719322A patent/EP1605936B1/de not_active Expired - Lifetime
- 2004-03-10 CA CA002518843A patent/CA2518843A1/en not_active Abandoned
- 2004-03-10 WO PCT/US2004/007686 patent/WO2004082678A1/en not_active Ceased
- 2004-03-10 AU AU2004222328A patent/AU2004222328B2/en not_active Ceased
- 2004-03-10 JP JP2006507140A patent/JP4673296B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4673296B2 (ja) | 2011-04-20 |
| CA2518843A1 (en) | 2004-09-30 |
| WO2004082678A1 (en) | 2004-09-30 |
| EP1605936B1 (de) | 2011-07-20 |
| US7189722B2 (en) | 2007-03-13 |
| EP1605936A4 (de) | 2008-08-06 |
| AU2004222328B2 (en) | 2009-10-08 |
| EP1605936A1 (de) | 2005-12-21 |
| AU2004222328A1 (en) | 2004-09-30 |
| US20060189593A1 (en) | 2006-08-24 |
| JP2006520388A (ja) | 2006-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535514T1 (de) | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten | |
| EP1606286A4 (de) | Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| EP1605936A4 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
| NO20072435L (no) | CGRP-reseptorantagonister | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| ATE464305T1 (de) | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| DE602007008434D1 (de) | Rezeptoren | |
| NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| EP1794133A4 (de) | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors | |
| ATE463245T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| ATE518852T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |